X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15664) 15664
Book Review (5117) 5117
Publication (1199) 1199
Book Chapter (110) 110
Newsletter (50) 50
Conference Proceeding (47) 47
Book / eBook (23) 23
Magazine Article (13) 13
Dissertation (12) 12
Reference (6) 6
Newspaper Article (3) 3
Transcript (2) 2
Data Set (1) 1
Paper (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (13711) 13711
humans (11068) 11068
male (6600) 6600
animals (5018) 5018
female (4835) 4835
hypertension (4704) 4704
angiotensin-converting enzyme inhibitors - therapeutic use (4472) 4472
angiotensin ii type 1 receptor blockers - therapeutic use (4296) 4296
hypertension - drug therapy (3831) 3831
angiotensin (3810) 3810
middle aged (3558) 3558
aged (3104) 3104
antihypertensive agents - therapeutic use (3037) 3037
pharmacology & pharmacy (2745) 2745
cardiac & cardiovascular systems (2417) 2417
rats (2334) 2334
blood pressure - drug effects (2295) 2295
treatment outcome (2272) 2272
peripheral vascular disease (2203) 2203
renin-angiotensin system (2083) 2083
risk factors (1990) 1990
blood-pressure (1980) 1980
renin-angiotensin system - drug effects (1920) 1920
tetrazoles - therapeutic use (1912) 1912
adult (1905) 1905
heart failure (1770) 1770
drug therapy, combination (1748) 1748
blood pressure (1721) 1721
hypertension - physiopathology (1636) 1636
angiotensin-ii (1586) 1586
mortality (1573) 1573
drug therapy (1544) 1544
medicine & public health (1517) 1517
angiotensin ii (1499) 1499
abridged index medicus (1421) 1421
angiotensin ii type 1 receptor blockers - pharmacology (1410) 1410
diabetes (1349) 1349
oxidative stress (1311) 1311
urology & nephrology (1304) 1304
heart failure - drug therapy (1283) 1283
research (1215) 1215
benzimidazoles - therapeutic use (1203) 1203
analysis (1189) 1189
enzymes (1163) 1163
care and treatment (1160) 1160
mice (1145) 1145
hypertension - complications (1144) 1144
ace inhibitors (1141) 1141
cardiology (1125) 1125
adrenergic beta-antagonists - therapeutic use (1121) 1121
losartan (1111) 1111
health aspects (1102) 1102
valsartan (1086) 1086
renin-angiotensin system - physiology (1004) 1004
angiotensin-converting enzyme inhibitors - pharmacology (999) 999
internal medicine (994) 994
medicine, general & internal (991) 991
losartan - therapeutic use (982) 982
calcium channel blockers - therapeutic use (966) 966
rodents (964) 964
time factors (940) 940
heart-failure (937) 937
disease models, animal (910) 910
expression (890) 890
angiotensin receptor antagonists (887) 887
physiological aspects (882) 882
physiology (876) 876
aged, 80 and over (874) 874
myocardial-infarction (854) 854
antihypertensive agents - pharmacology (836) 836
inflammation (827) 827
cardiovascular disease (821) 821
double-blind method (821) 821
prevention (813) 813
risk (803) 803
angiotensin receptor antagonists - therapeutic use (800) 800
prospective studies (783) 783
rats, sprague-dawley (773) 773
cardiovascular (759) 759
endocrinology & metabolism (757) 757
fibrosis (748) 748
disease (745) 745
randomized controlled trials as topic (737) 737
tetrazoles - pharmacology (728) 728
diuretics - therapeutic use (727) 727
dose-response relationship, drug (723) 723
disease progression (721) 721
valine - analogs & derivatives (720) 720
therapy (697) 697
renin (696) 696
double-blind (680) 680
aldosterone (670) 670
cardiovascular diseases (666) 666
clinical trials as topic (666) 666
heart failure - physiopathology (666) 666
medicine, research & experimental (665) 665
nephropathy (664) 664
angiotensin ii type 1 receptor blockers - adverse effects (663) 663
angiotensin-converting enzyme (662) 662
medicine (662) 662
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15215) 15215
Japanese (180) 180
German (168) 168
Russian (50) 50
Spanish (46) 46
French (44) 44
Chinese (39) 39
Italian (24) 24
Danish (11) 11
Czech (8) 8
Hungarian (8) 8
Polish (8) 8
Swedish (6) 6
Turkish (6) 6
Ukrainian (5) 5
Korean (4) 4
Finnish (3) 3
Portuguese (3) 3
Dutch (2) 2
Norwegian (2) 2
Serbian (2) 2
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Hypertension, ISSN 0194-911X, 06/2012, Volume 59, Issue 6, pp. 1132 - 1138
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2006, Volume 354, Issue 16, pp. 1685 - 1697
Persons with prehypertension (formerly, “borderline hypertension”) were randomly assigned in a blinded fashion to receive two years of candesartan or placebo,... 
UNITED-STATES | SPONTANEOUSLY HYPERTENSIVE RATS | MEDICINE, GENERAL & INTERNAL | NORMAL BLOOD-PRESSURE | METABOLIC CHARACTERISTICS | RISK-FACTORS | CONVERTING-ENZYME-INHIBITOR | CLINICAL-TRIAL | BORDERLINE HYPERTENSION | PREVENTION | PROGRESSION | Antihypertensive Agents - pharmacology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Tetrazoles - pharmacology | Dyslipidemias - complications | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Biphenyl Compounds - therapeutic use | Feasibility Studies | Incidence | Biphenyl Compounds - pharmacology | Hypertension - prevention & control | Adult | Female | Blood Pressure - drug effects | Hypertension - epidemiology | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Obesity - complications | Logistic Models | Obesity - physiopathology | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Benzimidazoles - pharmacology | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Dyslipidemias - physiopathology | Hypertension | Dosage and administration | Research | Drug therapy | Candesartan | Automation | Blood pressure | Lifestyles | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9638, pp. 547 - 553
Summary Background Angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors are known to reduce proteinuria. Their combination... 
Internal Medicine | COOPERATE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | RENIN-ANGIOTENSIN SYSTEM | DISEASE | PROTEINURIA | CONVERTING ENZYME-INHIBITORS | COMBINATION | NEPHROPATHY | II RECEPTOR BLOCKERS | PROGRESSION | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Ramipril - administration & dosage | Proteinuria - chemically induced | Cardiovascular Diseases - complications | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Benzimidazoles - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Benzimidazoles - therapeutic use | Kidney - drug effects | Double-Blind Method | Diabetes Mellitus - drug therapy | Proteinuria - metabolism | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Creatinine - urine | Benzoates - administration & dosage | Creatinine - blood | Aged | Urine | Drugs | Studies | Kidneys | Disease | Clinical trials | Risk | ACE inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2009, Volume 361, Issue 1, pp. 40 - 51
This study aimed to determine whether early administration of drugs that block the renin–angiotensin system slows the progression of change in glomerular... 
CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | STRUCTURAL-FUNCTIONAL RELATIONSHIPS | CORTICAL INTERSTITIUM | BLOOD-PRESSURE CONTROL | EARLY NATURAL-HISTORY | RETINOPATHY | ANGIOTENSIN-CONVERTING ENZYME | NEPHROPATHY | PROGRESSION | ENDOTHELIAL GROWTH-FACTOR | Retina - drug effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Male | Albuminuria | Angiotensin II Type 1 Receptor Blockers - pharmacology | Enalapril - therapeutic use | Enalapril - adverse effects | Mesangial Cells - drug effects | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Diabetic Nephropathies - prevention & control | Double-Blind Method | Diabetes Mellitus, Type 1 - physiopathology | Kidney Glomerulus - drug effects | Diabetes Mellitus, Type 1 - pathology | Kaplan-Meier Estimate | Losartan - pharmacology | Logistic Models | Kidney Glomerulus - pathology | Disease Progression | Diabetes Mellitus, Type 1 - drug therapy | Diabetic Retinopathy - prevention & control | Enalapril - pharmacology | Losartan - therapeutic use | Mesangial Cells - pathology | Losartan - adverse effects | Renin-Angiotensin System - drug effects | Retina - pathology | Diabetic retinopathy | Control | Usage | Enalapril | Type 1 diabetes | Patient outcomes | Losartan | Enalaprilat | Drug therapy | Kidneys | Diabetes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Science, ISSN 0036-8075, 4/2011, Volume 332, Issue 6027, pp. 361 - 365
Angiotensin II (AngII) mediates progression of aortic aneurysm, but the relative contribution of its type 1 (AT1) and type 2 (AT2) receptors remains unknown.... 
Connective tissues | Receptors | Root growth | Medical treatment | REPORTS | Aneurysms | Placebos | Aorta | Mice | Aortic aneurysm | Marfan syndrome | PATHOGENESIS | ACTIVATION | MECHANISM | MULTIDISCIPLINARY SCIENCES | MARFAN-SYNDROME | MOUSE MODEL | GROWTH | SMOOTH-MUSCLE-CELLS | BLOCKADE | CONTRIBUTES | EXPRESSION | Aortic Aneurysm - metabolism | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors | Aortic Rupture - metabolism | Angiotensin II Type 1 Receptor Blockers - pharmacology | Enalapril - therapeutic use | MAP Kinase Signaling System | Marfan Syndrome - drug therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aortic Rupture - prevention & control | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Aortic Aneurysm - pathology | Aortic Aneurysm - prevention & control | Disease Models, Animal | Receptor, Angiotensin, Type 2 - genetics | Angiotensin II - metabolism | Signal Transduction | Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors | Losartan - pharmacology | Aortic Rupture - pathology | Disease Progression | Mice, Knockout | Animals | Enalapril - pharmacology | Receptor, Angiotensin, Type 2 - metabolism | Mitogen-Activated Protein Kinase 3 - metabolism | Aortic Aneurysm - drug therapy | Losartan - therapeutic use | Marfan Syndrome - metabolism | Marfan Syndrome - pathology | Transforming Growth Factor beta - metabolism | Mitogen-Activated Protein Kinase 1 - metabolism | Aortic aneurysms | Development and progression | Genetic aspects | Health aspects | Angiotensin | Signal transduction | Peptides | Cellular biology | Coronary vessels | Rodents | Index Medicus | Progressions | Inhibitors | Blocking | Attenuation | Kinases
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9647, pp. 1394 - 1402
Summary Background Results of previous studies suggest that renin-angiotensin system blockers might reduce the burden of diabetic retinopathy. We therefore... 
Internal Medicine | EURODIAB PROSPECTIVE COMPLICATIONS | MORTALITY | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | DIRECT PROGRAM | RENIN-ANGIOTENSIN SYSTEM | MICROALBUMINURIA | CARDIOVASCULAR-DISEASE | MELLITUS | BLOOD-FLOW | HYPERTENSION | Hypoglycemic Agents - therapeutic use | Severity of Illness Index | Diabetic Retinopathy - drug therapy | Angiotensin II Type 1 Receptor Blockers - adverse effects | Double-Blind Method | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Diabetic Retinopathy - classification | Male | Treatment Outcome | Diabetes Mellitus, Type 1 - complications | Diabetes Mellitus, Type 1 - drug therapy | Adolescent | Adult | Female | Tetrazoles - therapeutic use | Diabetic Retinopathy - etiology | Tetrazoles - adverse effects | Benzimidazoles - adverse effects | Insulin - therapeutic use | Benzimidazoles - therapeutic use | Prevention | Diabetic retinopathy | Complications and side effects | Candesartan | Type 1 diabetes | Dosage and administration | Drug therapy | Risk factors | Studies | Clinical trials | Photographs | Diabetes | Pressure measurement | Patients | Index Medicus | Abridged Index Medicus | Benzimidazoles | Tetrazoles | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | Hypoglycemic Agents | MEDICAL AND HEALTH SCIENCES | Type 1 | drug therapy | complications | Diabetes Mellitus | classification | Insulin | etiology | adverse effects | therapeutic use | Diabetic Retinopathy
Journal Article
Hypertension, ISSN 0194-911X, 10/2009, Volume 54, Issue 4, pp. 716 - 723
The aim of this study was to compare the effects between calcium channel blockers and diuretics when used in combination with angiotensin II receptor blocker... 
Ambulatory blood pressure | Pulse wave velocity | Central blood pressure | Angiotensin II receptor blocker | Thiazide diuretic | Calcium channel blocker | thiazide diuretic | PULSE-WAVE VELOCITY | AZELNIDIPINE | CARDIOVASCULAR EVENTS | pulse wave velocity | RANDOMIZED TRIAL | ATENOLOL | AMLODIPINE | REDUCTION | central blood pressure | calcium channel blocker | angiotensin II receptor blocker | PERIPHERAL VASCULAR DISEASE | ambulatory blood pressure | ANTIHYPERTENSIVE THERAPY | HEART-RATE | CENTRAL BLOOD-PRESSURE | Single-Blind Method | Prospective Studies | Tetrazoles - pharmacology | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Male | Azetidinecarboxylic Acid - analogs & derivatives | Angiotensin II Type 1 Receptor Blockers - pharmacology | Azetidinecarboxylic Acid - therapeutic use | Time Factors | Hydrochlorothiazide - pharmacology | Azetidinecarboxylic Acid - pharmacology | Female | Blood Pressure - drug effects | Aorta - physiopathology | Imidazoles - therapeutic use | Drug Therapy, Combination | Diuretics - pharmacology | Japan | Treatment Outcome | Imidazoles - pharmacology | Calcium Channel Blockers - pharmacology | Hypertension - physiopathology | Dihydropyridines - therapeutic use | Dihydropyridines - pharmacology | Diuretics - therapeutic use | Tetrazoles - therapeutic use | Aged | Hydrochlorothiazide - therapeutic use | Index Medicus
Journal Article